DE3584866D1 - Hybridpartikel-immunogene. - Google Patents

Hybridpartikel-immunogene.

Info

Publication number
DE3584866D1
DE3584866D1 DE8585111431T DE3584866T DE3584866D1 DE 3584866 D1 DE3584866 D1 DE 3584866D1 DE 8585111431 T DE8585111431 T DE 8585111431T DE 3584866 T DE3584866 T DE 3584866T DE 3584866 D1 DE3584866 D1 DE 3584866D1
Authority
DE
Germany
Prior art keywords
atcc
september
deposited
expression
dna sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE8585111431T
Other languages
English (en)
Inventor
Pablo D T Valenzuela
George Kuo
Philip J Barr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24608410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3584866(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DE3584866D1 publication Critical patent/DE3584866D1/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE8585111431T 1984-09-12 1985-09-10 Hybridpartikel-immunogene. Revoked DE3584866D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65032384A 1984-09-12 1984-09-12

Publications (1)

Publication Number Publication Date
DE3584866D1 true DE3584866D1 (de) 1992-01-23

Family

ID=24608410

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585111431T Revoked DE3584866D1 (de) 1984-09-12 1985-09-10 Hybridpartikel-immunogene.

Country Status (6)

Country Link
EP (1) EP0175261B1 (de)
JP (3) JPH07108920B2 (de)
AT (1) ATE70308T1 (de)
CA (1) CA1263618A (de)
DE (1) DE3584866D1 (de)
HK (1) HK140195A (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707357A (en) * 1984-06-26 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Immunologically active peptides capable of inducing immunization against malaria and genes encoding therefor
ZA855232B (en) * 1984-07-23 1986-02-26 Univ New York Protective peptide antigen corresponding to plasmodium falciparum circumsporozoite protein
US4826957A (en) * 1985-07-12 1989-05-02 New York University Immunogenic recombinant yeast expression product and method for purifying it
DE3788902T3 (de) * 1986-06-17 2004-11-25 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Hepatitis-Delta-Diagnostika und Impfstoffe, ihre Herstellung und Verwendung.
GB2195340A (en) * 1986-08-22 1988-04-07 Malcolm Alistair Mccrae Anti-viral vaccine
US5041385A (en) * 1986-11-01 1991-08-20 Oxford Gene Systems Limited Vector expressing fusion proteins and particles
HUT51332A (en) * 1987-01-30 1990-04-28 Smithkline Biolog Process for expressing p.falciparum cirkumsporozoita protein by yeast
EP0278940A3 (de) * 1987-01-30 1988-12-07 Smithkline Biologicals S.A. Hepatitis-B-Virus-Oberflächenantigene und sie enthaltende hybride Antigene
NZ219515A (en) * 1987-02-10 1989-09-27 Wellcome Found Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope
NZ219516A (en) * 1987-02-10 1991-02-26 Wellcome Found Fusion proteins of hbcag (hepatitis b virus core antigen)
EP0300213A1 (de) * 1987-06-22 1989-01-25 Hexal-Pharma Gentechnik GmbH & Co. KG Virale, immunogen wirksame Peptidpartikel von Hepatitis A
FR2635532B1 (fr) * 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
EP0396653A1 (de) * 1988-08-30 1990-11-14 Applied Research Systems ARS Holding N.V. Rekombinante schmelz-proteine zur modifizierung der hormonabscheidung
JPH02115129A (ja) * 1988-10-21 1990-04-27 Kokuritsu Yobou Eisei Kenkyusho 抗ウィルス剤
US5648241A (en) * 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
EP0652967B1 (de) * 1990-08-15 1998-02-04 Therion Biologics Corporation Selbstständig zusammenfügende replikationsdefekte hybride viruspartikel
IT1241003B (it) * 1990-11-05 1993-12-27 Sorin Biomedica Spa Procedimento per la purificazione di un polipeptide ricombinante hdag equivalente, polipeptide hdag equivalente e saggi immunologici che lo utilizzano
EP0491077A1 (de) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten
GB9102126D0 (en) * 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
US6040169A (en) 1991-01-31 2000-03-21 Medical Research Council Herpes simplex virus-1 deletion variants and vaccines thereof
ES2129461T3 (es) * 1991-11-16 1999-06-16 Smithkline Beecham Biolog Proteina hibrida entre cs de plasmodium y hbsag.
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
GB9202933D0 (en) * 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
US6169171B1 (en) 1992-02-27 2001-01-02 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBSAG
US5928902A (en) * 1992-02-27 1999-07-27 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBsAg
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
MY111880A (en) * 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
ES2160601T3 (es) * 1992-09-24 2001-11-16 Brigham & Womens Hospital Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina.
ZA937034B (en) * 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
AU5838794A (en) * 1993-01-16 1994-08-15 British Bio-Technology Limited Hybrid particle-forming protein comprising a particle-inducing segment and a plurality of antigens
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
ATE286511T1 (de) 1999-02-17 2005-01-15 Pfizer Prod Inc Fusionsproteine mit trägern welche eine doppelte immunantwort induzieren
AU2010277222A1 (en) * 2009-07-29 2012-03-08 Bryce Malcolm Buddle Polymer particles and uses thereof
KR101328752B1 (ko) * 2012-03-19 2013-11-13 최석명 과채류용 멀칭비닐을 이용한 덮개 및 이의 제조방법
US10208290B2 (en) * 2013-06-21 2019-02-19 The Johns Hopkins University Virion display array for profiling functions and interactions of human membrane proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
GR76274B (de) * 1981-08-04 1984-08-04 Univ California
EP0094506B1 (de) * 1982-04-15 1988-10-12 Merck & Co. Inc. DNS Klonierungsvektor TG1, Derivate, Produkte und Verfahren
GB8421282D0 (en) * 1984-08-22 1984-09-26 Connaught Lab Multispecific antigenic proteins

Also Published As

Publication number Publication date
CA1263618A (en) 1989-12-05
JP2659084B2 (ja) 1997-09-30
ATE70308T1 (de) 1991-12-15
JPH07108920B2 (ja) 1995-11-22
JPH0746997A (ja) 1995-02-21
EP0175261B1 (de) 1991-12-11
EP0175261A2 (de) 1986-03-26
JPH0739379A (ja) 1995-02-10
EP0175261A3 (en) 1988-01-07
HK140195A (en) 1995-09-08
JP2531498B2 (ja) 1996-09-04
JPS61129135A (ja) 1986-06-17

Similar Documents

Publication Publication Date Title
DE3584866D1 (de) Hybridpartikel-immunogene.
CA2020668A1 (en) Fused or hybrid protein comprising viral antigen and lymphokine
EP0278940A3 (de) Hepatitis-B-Virus-Oberflächenantigene und sie enthaltende hybride Antigene
IE792494L (en) Recombinant dna and their method of production
ES8305419A1 (es) Un peptido
EP0370458A3 (de) Von synthetischer DNS abgeleitete rekombinante HIV-1-Antigene
WO2000039302A3 (en) Improved expression of hiv polypeptides and production of virus-like particles
ES8703520A1 (es) Procedimiento de preparar particulas que contienen secuencias de aminoacidos y que tienen propiedades inmunogenas
HUT43630A (en) Mammalian interleukine-4 and process for producing it
PT96097A (pt) Processo para a preparacao de antigene de toxoplasma gondii bem como de meios de diagnostico, vacinas e anticorpos deles derivados
CA2089753A1 (en) Interleukin-2-leukotoxin gene fusions and uses therefor
HK140095A (en) Hepatitis surface antigen particle vaccine
GR3007031T3 (de)
DE3888290D1 (de) Mutanten des infektiösen bovinen Rhinotracheitisvirus, Vakzine die sie enthalten, Verfahren zu ihrer Herstellung und ihrer Verwendung.
AU1321988A (en) The cloning of malaria-specific dna sequences: isolation of the gene for the 140 kd protein
EP1433851A3 (de) Verbesserte exprimierung von HIV Polypeptiden und Herstellung von virusähnliche Partikeln
MY102686A (en) Recombinant dna molecules and their method of production.
TH6216EX (th) แอนติเจนที่ผิวของเฮพาไตติสมีไวรัสและแอนติเจนถูกผสม ซึ่งมีแอนติเจนที่ผิวของเฮปาไตติสมีไวรัส
TH6216A (th) แอนติเจนที่ผิวของเฮพาไตติสมีไวรัสและแอนติเจนถูกผสม ซึ่งมีแอนติเจนที่ผิวของเฮปาไตติสมีไวรัส

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation